Cas:91285-17-5 2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate manufacturer & supplier

We serve Chemical Name:2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate CAS:91285-17-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate

Chemical Name:2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate
CAS.NO:91285-17-5
Synonyms:7-(2-Acetoxyethoxy)xanthone-3-carboxamide;9H-Xanthene-3-carboxamide,7-[2-(acetyloxy)ethoxy]-9-oxo;7-(2-Acetoxyethyl)-9-benzyl-1,3-dimethyl-6-hydroxy-9H-8-oxo-pyrimido[2,1-f]purine-2,4-dione
Molecular Formula:C21H21N5O6
Molecular Weight:439.42100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:129.83000
Exact Mass:439.14900
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-(2-Acetoxyethoxy)xanthone-3-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-(2-Acetoxyethyl)-9-benzyl-1,3-dimethyl-6-hydroxy-9H-8-oxo-pyrimido[2,1-f]purine-2,4-dione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9H-Xanthene-3-carboxamide,7-[2-(acetyloxy)ethoxy]-9-oxo Use and application,9H-Xanthene-3-carboxamide,7-[2-(acetyloxy)ethoxy]-9-oxo technical grade,usp/ep/jp grade.


Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. 2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate manufacturer With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. 2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate supplier With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. 2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate vendor The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-(9-Benzyl-6-hydroxy-1,3-dimethyl-2,4,8-trioxo-1,2,3,4,8,9-hexah ydropyrimido[2,1-f]purin-7-yl)ethyl acetate factory With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.